SGEN * Stock Overview
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.
Notes are coming soon
Seagen Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2,994.97|
|52 Week High||US$2,994.97|
|52 Week Low||US$2,994.97|
|1 Month Change||n/a|
|3 Month Change||n/a|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-22.98%|
Recent News & Updates
|SGEN *||MX Biotechs||MX Market|
Return vs Industry: Insufficient data to determine how SGEN * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how SGEN * performed against the MX Market.
|SGEN * volatility|
|SGEN * Average Weekly Movement||n/a|
|Biotechs Industry Average Movement||0%|
|Market Average Movement||0%|
|10% most volatile stocks in MX Market||0%|
|10% least volatile stocks in MX Market||0%|
Stable Share Price: Insufficient data to determine SGEN *'s volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine SGEN *'s volatility change over the past year.
About the Company
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases.
Seagen Inc. Fundamentals Summary
|SGEN * fundamental statistics|
Is SGEN * overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SGEN * income statement (TTM)|
|Cost of Revenue||US$1.68b|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 15, 2023
|Earnings per share (EPS)||-3.43|
|Net Profit Margin||-34.16%|
How did SGEN * perform over the long term?See historical performance and comparison